$1.5 Million Boost to Endowed Chair from GSK Positions U of A to Expand...
New investment in long-standing partnership will help create jobs and attract top talent in burgeoning biotech industry, says founding chair. MISSISSAUGA, ON — Biopharma company GSK is investing $1.5...
View ArticleSurvey of Medical Experts Reveals Opportunities to Address Organ Damage Risk...
Survey examined healthcare professional (HCP) approaches to preventing organ damage – which impacts many people living with lupus within five years of diagnosis HCPs reported a need for earlier...
View ArticleGSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company BELLUS...
Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough...
View Article$3 Million Joint Investment by GSK and U of T to Launch the GSK Chair in...
The new chair will aim to close gaps in vaccine education for students and practicing healthcare professionals, with a focus on pharmacists MISSISSAUGA, ON – The University of Toronto (U of T) and...
View ArticleBiopharma Company GSK Grants $1 Nillion to Halifax-based Canadian Center for...
Grant recognizes CCfV’s national leadership and Nova Scotian contribution to Canada’s research capabilities, expected to attract top talent. MISSISSAUGA, ON — GSK announces a $1 million grant to...
View ArticleGSK Completes Acquisition of BELLUS Health
MISSISSAUGA, ON — GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives...
View ArticleGSK’s Arexvy, the First Respiratory Syncytial Virus (RSV) Vaccine for Older...
Canadians aged 60 years and older can now better protect themselves against RSV disease Approval of Arexvy was based on a comprehensive Phase III clinical trial program that showed high vaccine...
View ArticleGSK Announces Largest Private Financial Contribution to CIHR’s Team Grants...
The $2 million contribution will support the investigation into evidence-based solutions to improve Canadians’ lung health. MISSISSAUGA, ON — GSK is investing $2 million in research to address...
View ArticleJemperli (Dostarlimab for Injection) Plus Carboplatin and Paclitaxel Approved...
Jemperli is the only immuno-oncology treatment approved for this patient population in combination with chemotherapy in Canada. An estimated 20-29% of all endometrial cancers are dMMR/MSI-H and...
View ArticleGSK Canada’s Submission for Momelotinib for the Treatment of Myelofibrosis...
Health Canada’s acceptance of the submission follows that of the Ministry of Health, Labour and Welfare (WHLW) in Japan and approval by the US Food and Drug Administration (FDA) and the European...
View Article
